185 related articles for article (PubMed ID: 34519101)
1. The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
Subramanian P; Gargani S; Palladini A; Chatzimike M; Grzybek M; Peitzsch M; Papanastasiou AD; Pyrina I; Ntafis V; Gercken B; Lesche M; Petzold A; Sinha A; Nati M; Thangapandi VR; Kourtzelis I; Andreadou M; Witt A; Dahl A; Burkhardt R; Haase R; Domingues AMJ; Henry I; Zamboni N; Mirtschink P; Chung KJ; Hampe J; Coskun Ü; Kontoyiannis DL; Chavakis T
Hepatology; 2022 Apr; 75(4):881-897. PubMed ID: 34519101
[TBL] [Abstract][Full Text] [Related]
2. Hepatic HuR protects against the pathogenesis of non-alcoholic fatty liver disease by targeting PTEN.
Tian M; Wang J; Liu S; Li X; Li J; Yang J; Zhang C; Zhang W
Cell Death Dis; 2021 Mar; 12(3):236. PubMed ID: 33664225
[TBL] [Abstract][Full Text] [Related]
3. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
4. RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression.
Wang Y; Tai YL; Way G; Zeng J; Zhao D; Su L; Jiang X; Jackson KG; Wang X; Gurley EC; Liu J; Liu J; Chen W; Wang XY; Sanyal AJ; Hylemon PB; Zhou H
Cell Biosci; 2022 Oct; 12(1):172. PubMed ID: 36224648
[TBL] [Abstract][Full Text] [Related]
5. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
7. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
8. CerS5 deficiency promotes liver fibrosis development in non-alcoholic fatty liver disease.
Chen J; Hao Y; Xu P; Bian D; Han L; Wu X; Zhuang Z; Wang J; Luo Y
Biochem Biophys Res Commun; 2023 Jul; 667():120-126. PubMed ID: 37216827
[TBL] [Abstract][Full Text] [Related]
9. Hepatic HuR modulates lipid homeostasis in response to high-fat diet.
Zhang Z; Zong C; Jiang M; Hu H; Cheng X; Ni J; Yi X; Jiang B; Tian F; Chang MW; Su W; Zhu L; Li J; Xiang X; Miao C; Gorospe M; de Cabo R; Dou Y; Ju Z; Yang J; Jiang C; Yang Z; Wang W
Nat Commun; 2020 Jun; 11(1):3067. PubMed ID: 32546794
[TBL] [Abstract][Full Text] [Related]
10. Key features of the environment promoting liver cancer in the absence of cirrhosis.
Zaki MYW; Mahdi AK; Patman GL; Whitehead A; Maurício JP; McCain MV; Televantou D; Abou-Beih S; Ramon-Gil E; Watson R; Cox C; Leslie J; Wilson C; Govaere O; Lunec J; Mann DA; Nakjang S; Oakley F; Shukla R; Anstee QM; Tiniakos D; Reeves HL
Sci Rep; 2021 Aug; 11(1):16727. PubMed ID: 34408183
[TBL] [Abstract][Full Text] [Related]
11. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.
Zhu H; Berkova Z; Mathur R; Sehgal L; Khashab T; Tao RH; Ao X; Feng L; Sabichi AL; Blechacz B; Rashid A; Samaniego F
Mol Cancer Res; 2015 May; 13(5):809-18. PubMed ID: 25678597
[TBL] [Abstract][Full Text] [Related]
12. Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis.
Mohammed S; Thadathil N; Ohene-Marfo P; Tran AL; Van Der Veldt M; Georgescu C; Oh S; Nicklas EH; Wang D; Haritha NH; Luo W; Janknecht R; Miller BF; Wren JD; Freeman WM; Deepa SS
Mol Cancer Res; 2023 Sep; 21(9):933-946. PubMed ID: 37204757
[TBL] [Abstract][Full Text] [Related]
13. Loss of hepatic Mboat7 leads to liver fibrosis.
Thangapandi VR; Knittelfelder O; Brosch M; Patsenker E; Vvedenskaya O; Buch S; Hinz S; Hendricks A; Nati M; Herrmann A; Rekhade DR; Berg T; Matz-Soja M; Huse K; Klipp E; Pauling JK; Wodke JA; Miranda Ackerman J; Bonin MV; Aigner E; Datz C; von Schönfels W; Nehring S; Zeissig S; Röcken C; Dahl A; Chavakis T; Stickel F; Shevchenko A; Schafmayer C; Hampe J; Subramanian P
Gut; 2021 May; 70(5):940-950. PubMed ID: 32591434
[TBL] [Abstract][Full Text] [Related]
14. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis.
Herrero-Cervera A; Vinué Á; Burks DJ; González-Navarro H
Diabetologia; 2019 Nov; 62(11):2143-2157. PubMed ID: 31388695
[TBL] [Abstract][Full Text] [Related]
15. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
17. Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase.
Salloum S; Jeyarajan AJ; Kruger AJ; Holmes JA; Shao T; Sojoodi M; Kim MH; Zhuo Z; Shroff SG; Kassa A; Corey KE; Khan SK; Lin W; Alatrakchi N; Schaefer EAK; Chung RT
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1297-1310. PubMed ID: 34118488
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
19. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.
Kumar S; Verma AK; Rani R; Sharma A; Wang J; Shah SA; Behari J; Salazar Gonzalez R; Kohli R; Gandhi CR
Hepatology; 2020 Nov; 72(5):1586-1604. PubMed ID: 32031683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
